Drug Patents owned by Bioxcel

1. List of Igalmi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11497711 BIOXCEL NA
Jun, 2039

(16 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

IGALMI family patents

17

United States

6

China

3

European Union

2

Japan

1

Taiwan, Province of China

1

Korea, Republic of

1

Israel

1

Singapore

1

Australia

1

EA

1

Canada

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic